Mylan Stretches Games Clock, Adds To Costs For Perrigo Takeover Play
This article was originally published in The Pink Sheet Daily
Executive Summary
Perrigo says Mylan shows “desperation” in targeting approval by 50% of its shareholders rather than the 80% approval it initially stated in its regulatory filing. A 50% threshold means Mylan would pay more in interest to lenders because it would be required to continue its takeover attempt longer than initially planned.
You may also be interested in...
Perrigo Gains 180-Day Exclusivity With ANDA Approval For Omeprazole Magnesium PPI
Perrigo receives approval for its ANDA for a Prilosec OTC equivalent and another for a generic of Advil Fast Relief. The firm includes those products in its outlook for $1 billion in new product sales over three years.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.